Author: Barua, Sanjay ; Rathore, Karishma ; Kumar, Ram ; Dhanda, Shweta ; Kamboj, Himanshu ; Tripathi, Bhupendra Nath ; Gaur, Mitesh ; Sharma, Deepak Kumar ; Kumar, Garvit ; Kumar, Naveen ; Mittal, Priyasi ; Verma, Assim ; Sharma, Shalini

Since 2019, Lumpy skin disease (LSD) has suddenly spread in many Asian countries, including India. LSD primarily occurs in cattle. However, recent LSD outbreaks in India have also revealed significant morbidity and production losses in buffaloes. This has raised concerns about the role of buffaloes in the epidemiology and transmission of LSD and necessitates the inclusion of buffaloes in the mass vaccination program for the prevention and control of the disease in the country. However, there is no significant data on the immune response in buffaloes following vaccination with the LSD vaccine. In this study, we evaluated antibody- and cell-mediated immune responses following vaccination with a newly developed live-attenuated LSD vaccine (Lumpi-ProVac^Ind). The detectable amount of anti-LSDV antibodies was observed at 1-2 months following vaccination, with a peak antibody titer at 3 months. Upon stimulation of the peripheral blood mononuclear cells (PBMCs) with the UV-inactivated LSDV antigen, there was a significant increase in CD8 + T cell counts in vaccinated animals as compared to the unvaccinated animals. Besides, vaccinated animals also showed a significant increase in IFN-γ levels upon antigenic stimulation of their PBMCs with LSDV antigen. In conclusion, the buffaloes also mount a potent antibody- and cell-mediated immune response following vaccination with Lumpi-ProVac^Ind.

31 Dec 2023·Virulence

Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India

Article

Author: Kumar, Ashok ; Gulati, Baldev R ; Tripathi, Bhupendra N ; Kumar, Ram ; Yousuf, Raja Wasim ; Bashir, Arif ; Kachhawaha, Subhash ; Barua, Sanjay ; Verma, Assim ; Dutt, Triveni ; Yadav, Vijaypal ; Tiwari, Hari Audh ; Vyas, Vithilesh ; Khandelwal, Nitin ; Riyesh, Thachamvally ; Munjal, Vijay Kumar ; Singh, Lokender ; Kumar, Amit ; Andrabi, Anjum ; Koul, Abhimanyu ; Chaudhary, Sarjeet ; Pathak, Anubha ; Gurav, Amol ; Bhardwaj, Bhupendra ; Nandi, Sukdeb ; Gupta, Madhurendu K ; Kumar, Sanjay ; Misri, Jyoti ; Bhati, Adrish ; Gaur, Mitesh ; Singh, Karam Pal ; Kaul, Rakesh ; Kumar, Naveen ; Godara, Bhagraj ; Pal, Yash ; Mehta, Vishal ; Kumar, Rajender ; Gautam, Siddharth ; Kumar, Garvit ; Chander, Yogesh ; Dedar, Ramesh Kumar ; Sharma, Deepak Kumar ; Mohanty, Ashok Kumar

Lumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization to induce protection against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed by using an Indian field strain, isolated in 2019 from cattle. The virus was attenuated by continuous passage (P = 50) in Vero cells. The vaccine (50^th LSDV passage in Vero cells, named as Lumpi-ProVac^Ind) did not induce any local or systemic reaction upon its experimental inoculation in calves (n = 10). At day 30 post-vaccination (pv), the vaccinated animals were shown to develop antibody- and cell-mediated immune responses and exhibited complete protection upon virulent LSDV challenge. A minimum Neethling response (0.018% animals; 5 out of 26,940 animals) of the vaccine was observed in the field trials conducted in 26,940 animals. There was no significant reduction in the milk yield in lactating animals (n = 10108), besides there was no abortion or any other reproductive disorder in the pregnant animals (n = 2889). Sero-conversion was observed in 85.18% animals in the field by day 30 pv.

01 Jan 2021·Cell Reports Medicine

Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection

Article

Author: Haanstra, Krista G ; Rodríguez, Esteban ; Sombroek, Claudia C ; Vervenne, Richard A W ; Puentes, Eugenia ; Hofman, Sam O ; Aguilo, Nacho ; Verreck, Frank A W ; Dijkman, Karin ; Martin, Carlos ; Vierboom, Michel P M ; Boot, Charelle ; Marinova, Dessislava ; Kocken, Clemens H M ; Thole, Jelle

To fight tuberculosis, better vaccination strategies are needed. Live attenuated Mycobacterium tuberculosis-derived vaccine, MTBVAC, is a promising candidate in the pipeline, proven to be safe and immunogenic in humans so far. Independent studies have shown that pulmonary mucosal delivery of Bacillus Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine available today, confers superior protection over standard intradermal immunization. Here we demonstrate that mucosal MTBVAC is well tolerated, eliciting polyfunctional T helper type 17 cells, interleukin-10, and immunoglobulins in the airway and yielding a broader antigenic profile than BCG in rhesus macaques. Beyond our previous work, we show that local immunoglobulins, induced by MTBVAC and BCG, bind to M. tuberculosis and enhance pathogen uptake. Furthermore, after pulmonary vaccination, but not M. tuberculosis infection, local T cells expressed high levels of mucosal homing and tissue residency markers. Our data show that pulmonary MTBVAC administration has the potential to enhance its efficacy and justifies further exploration of mucosal vaccination strategies in preclinical efficacy studies.

100 Deals associated with Rubella vaccine, live-attenuated(Shanghai Institute of Biological Products)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BJ01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rubella	CN	Shanghai Institute of Biological Products Co., Ltd.	01 Jan 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rubella vaccine, live-attenuated(Shanghai Institute of Biological Products)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation